β-III tubulin fragments inhibit α-synuclein accumulation in models of multiple system atrophy

Journal of Biological Chemistry

Volumn 289, Issue 35, 2014, Pages 24374-24382

  Suzuki, Yasuyo ^a   Jin, Chenghua ^a   Iwase, Tamaki ^b   Yazawa, Ikuru ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b Department of Neurology Nagoya City Koseiin Medical Welfare Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALS;

BRAIN TISSUE; CULTURED CELL; MOUSE MODELS; MULTIPLE SYSTEM ATROPHIES; OLIGODENDROCYTES; PEPTIDE FRAGMENTS; THERAPEUTIC STRATEGY; TRANSGENIC MICE;

NEURONS;

ALPHA SYNUCLEIN; BETA III TUBULIN; BETA TUBULIN; UNCLASSIFIED DRUG; BETA3 TUBULIN, MOUSE; PRIMER DNA; PROTEIN BINDING; TUBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BIOACCUMULATION; BRAIN TISSUE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; HUMAN; HUMAN TISSUE; MOUSE; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SHY DRAGER SYNDROME; TRANSGENIC MOUSE; ANIMAL; CELL CULTURE; CHEMISTRY; METABOLISM; NERVE CELL; NUCLEOTIDE SEQUENCE; PHYSIOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; BASE SEQUENCE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DNA PRIMERS; MICE; MICE, TRANSGENIC; MULTIPLE SYSTEM ATROPHY; NEURONS; PROTEIN BINDING; TUBULIN;

EID: 84906861214     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.557215     Document Type: Article

References (36)

1. Graham, J. G., and Oppenheimer D. R. (1969) Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 32, 28-34
2. Gilman, S., Low P. A., Quinn, N., Albanese, A., Ben-Shlomo, Y., Fowler, C. J., Kaufmann, H., Klockgether, T., Lang, A. E., Lantos, P. L., Litvan, I., Mathias, C. J., Oliver, E., Robertson, D., Schatz, I., and Wenning, G. K. (1999) Consensus statement on the diagnosis of multiple system atrophy. J. Neurol. Sci. 163, 94-98 (Pubitemid 29155424)
3. Papp, M. I., Kahn, J. E., and Lantos, P. L. (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J. Neurol. Sci. 94, 79-100 (Pubitemid 20019446)
4. Arima, K., Uéda, K., Sunohara, N., Arakawa, K., Hirai, S., Nakamura, M., Tonozuka-Uehara, H., and Kawai, M. (1998) NACP/α-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol. 96, 439-444 (Pubitemid 28474750)
5. Tu, P. H., Galvin, J. E., Baba, M., Giasson, B., Tomita, T., Leight, S., Nakajo, S., Iwatsubo, T., Trojanowski, J. Q., and Lee, V. M.-Y. (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann. Neurol. 44, 415-422 (Pubitemid 28421453)
6. Spillantini, M. G., Crowther, R. A., Jakes, R., Cairns, N. J., Lantos, P. L., and Goedert, M. (1998) Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205-208 (Pubitemid 28381082)
7. Goedert, M. (2001) α-Synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492-501
8. Asi, Y. T., Simpson, J. E., Heath, P. R., Wharton, S. B., Lees, A. J., Revesz, T., Houlden, H., and Holton, J. L. (2014) α-Synuclein mRNA expression in oligodendrocytes in MSA. Glia 62, 964-970
9. Kahle, P. J., Neumann, M., Ozmen, L., Muller, V., Jacobsen, H., Spooren, W., Fuss, B., Mallon, B., Macklin, W. B., Fujiwara, H., Hasegawa, M., Iwatsubo, T., Kretzschmar, H. A., and Haass, C. (2002) Hyperphosphorylation and insolubility of α-synuclein in transgenic mouse oligodendrocytes. EMBO Rep. 3, 583-588 (Pubitemid 34752460)
10. Yazawa, I., Giasson, B. I., Sasaki, R., Zhang, B., Joyce, S., Uryu, K., Trojanowski, J. Q., and Lee, V. M.-Y. (2005) Mouse model of multiple system atrophy: α-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45, 847-859 (Pubitemid 40395264)
11. Shults, C. W., Rockenstein, E., Crews, L., Adame, A., Mante, M., Larrea, G., Hashimoto, M., Song, D., Iwatsubo, T., Tsuboi, K., and Masliah, E. (2005) Neurological and neurodegenerative alterations in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J. Neurosci. 25, 10689-10699 (Pubitemid 41681917)
12. Nakayama, K., Suzuki, Y., and Yazawa, I. (2009) Microtubule depolymerization suppresses α-synuclein accumulation in a mouse model of multiple system atrophy. Am. J. Pathol. 174, 1471-1480
13. Ito, H., Nakayama, K., Jin, C., Suzuki, Y., and Yazawa, I. (2012) α-Synuclein accumulation reduces GABAergic inhibitory transmission in a model of multiple system atrophy. Biochem. Biophys. Res. Commun. 428, 348-353
14. Lantos, P. L., and Papp, M. I. (1994) Cellular pathology of multiple system atrophy: a review. J. Neurol. Neurosurg. Psychiatry 57, 129-133 (Pubitemid 24050449)
15. Suzuki, Y., Jin, C., and Yazawa, I. (2014) Cystatin C triggers neuronal degeneration in a model of multiple system atrophy. Am. J. Pathol. 184, 790-799
16. Nakayama, K., Suzuki, Y., and Yazawa, I. (2012) Binding of neuronal α-synuclein to β-III tubulin and accumulation in a model of multiple system atrophy. Biochem. Biophys. Res. Commun. 417, 1170-1175
17. Yazawa, I., Nakase, H., and Kurisaki, H. (1999) Abnormal dentatorubral-pallidoluysian atrophy (DRPLA) protein complex is pathologically ubiquitinated in DRPLA brains. Biochem. Biophys. Res. Commun. 260, 133-138 (Pubitemid 29351797)
18. Hemsley, A., Arnheim, N., Toney, M. D., Cortopassi, G., and Galas, D. J. (1989) A simple method for site-directed mutagenesis using the polymerase chain reaction. Nucleic Acids Res. 17, 6545-6551 (Pubitemid 19215577)
19. Kajikawa, M., Li, P. C., Goto, E., Miyashita, N., Aoki-Kawasumi, M., Mito-Yoshida, M., Ikegaya, M., Sugita, Y., and Ishido, S. (2012) The intertrans-membrane region of Kaposi's sarcoma-associated herpesvirus modulator of immune recognition 2 contributes to B7-2 downregulation. J. Virol. 86, 5288-5296
20. Suzuki, Y., Nakayama, K., Hashimoto, N., and Yazawa, I. (2010) Proteolytic processing regulates pathological accumulation in dentatorubral-pallidoluysian atrophy. FEBS J. 277, 4873-4887
21. Payton, J. E., Perrin, R. J., Clayton, D. F., and George, J. M. (2001) Protein-protein interactions of α-synuclein in brain homogenates and transfected cells. Brain Res. Mol. Brain Res. 95, 138-145 (Pubitemid 33000372)
22. Alim, M. A., Hossain, M. S., Arima, K., Takeda, K., Izumiyama, Y., Nakamura, M., Kaji, H., Shinoda, T., Hisanaga, S., and Ueda, K. (2002) Tubulin seeds α-synuclein fibril formation. J. Biol. Chem. 277, 2112-2117 (Pubitemid 34968795)
23. Lee, H. J., Khoshaghideh, F., Lee, S., and Lee, S. J. (2006) Impairment of microtubule-dependent trafficking by overexpression of α-synuclein. Eur. J. Neurosci. 24, 3153-3162 (Pubitemid 44952647)
24. Alim, M. A., Ma, Q. L., Takeda, K., Aizawa, T., Matsubara, M., Nakamura, M., Asada, A., Saito, T., Kaji, H., Yoshii, M., Hisanaga, S., and Uéda, K. (2004) Demonstration of a role for α-synuclein as a functional microtubule-associated protein. J. Alzheimers Dis. 6, 435-442; discussion 443-449
25. Prots, I., Veber, V., Brey, S., Campioni, S., Buder, K., Riek, R., Böhm, K. J., and Winner, B. (2013) α-Synuclein oligomers impair neuronal microtubule-kinesin interplay. J. Biol. Chem. 288, 21742-21754
26. Lien, S., and Lowman, H. B. (2003) Therapeutic peptides. Trends Biotechnol. 21, 556-562 (Pubitemid 37415008)
27. Vlieghe, P., Lisowski, V., Martinez, J., and Khrestchatisky, M. (2010) Synthetic therapeutic peptides: science and market. Drug Discov. Today 15, 40-56
28. Pardridge, W. M. (2002) Drug and gene delivery to the brain: the vascular route. Neuron 36, 555-558
29. Dietz, G. P., and Bähr, M. (2004) Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell Neurosci. 27, 85-131 (Pubitemid 39370094)
30. Tiwari, S. B., and Amiji, M. M. (2006) A review of nanocarrier-based CNS delivery systems. Curr. Drug Deliv. 3, 219-232 (Pubitemid 43738987)
31. Skovronsky, D. M., Lee, V. M.-Y., and Trojanowski, J. Q. (2006) Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol. 1, 151-170
32. Lashuel, H. A., Overk, C. R., Oueslati, A., and Masliah, E. (2013) The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38-48
33. Bodles, A. M., El-Agnaf, O. M., Greer, B., Guthrie, D. J., and Irvine, G. B. (2004) Inhibition of fibril formation and toxicity of a fragment of α-synuclein by an N-methylated peptide analogue. Neurosci. Lett. 359, 89-93 (Pubitemid 38446646)
34. El-Agnaf, O. M., Paleologou, K. E., Greer, B., Abogrein, A. M., King, J. E., Salem, S. A., Fullwood, N. J., Benson, F. E., Hewitt, R., Ford, K. J., Martin, F. L., Harriott, P., Cookson, M. R., and Allsop, D. (2004) A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J. 18, 1315-1317 (Pubitemid 39561588)
35. Divinski, I., Holtser-Cochav, M., Vulih-Schultzman, I., Steingart, R. A., and Gozes, I. (2006) Peptide neuroprotection through specific interaction with brain tubulin. J. Neurochem. 98, 973-984 (Pubitemid 44051296)
36. Fleming, S. M., Mulligan, C. K., Richter, F., Mortazavi, F., Lemesre, V., Frias, C., Zhu, C., Stewart, A., Gozes, I., Morimoto, B., and Chesselet, M. F. (2011) A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing α-synuclein shows improvement in motor function and reduction of α-synuclein inclusions. Mol. Cell Neurosci. 46, 597-606